Completed
PHASE1
INTERVENTIONAL
NCT06289504
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This study will look at how CagriSema affects the blood levels of atorvastatin and warfarin. The study will look at the levels of warfarin and atorvastatin in the blood before the participant starts taking CagriSema and if this changes after the participant has taken CagriSema. The study will also investigate the effect of warfarin before and after the participant takes CagriSema and assess if the injection site affects the level of CagriSema in the blood. The study will last for about 8 months.
Interventions
Name:
Cagrilintide
Type:
DRUG
Description:
Cagrilintide will be administered subcutaneously once weekly.
Name:
Semaglutide
Type:
DRUG
Description:
Semaglutide will be administered subcutaneously once weekly.
Name:
Atorvastatin
Type:
DRUG
Description:
Atorvastatin will be administered as a single dose orally 2 times during the study.
Name:
Warfarin
Type:
DRUG
Description:
Warfarin will be administered as a single dose orally 2 times during the study.
Primary Outcomes
Measure:
AUC0-72hours,atorv,SD: Area under the atorvastatin plasma concentration-time curve from time 0 to 72 hours after a single dose of atorvastatin without CagriSema exposure and at CagriSema steady state
TimeFrame:
Day 1 (pre-dose to 72 hours post-dose) and day 171 (pre-dose to 72 hours post-dose)
Description:
Measured in hours\*nanomoles per liter (hours\*nmol/L).
Measure:
AUC0-168hours,S-war,SD: Area under the S-warfarin plasma concentration-time curve from time 0 to 168 hours after a single dose of warfarin without CagriSema exposure and at CagriSema steady state
TimeFrame:
Day 8 (pre-dose to 168 hours post-dose) and day 178 (pre-dose to 168 hours post-dose)
Description:
Measured in hours\*nmol/L.
Trial Information
NCT ID
NCT06289504
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE1
Sponsor
Novo Nordisk A/S
Last Updated
December 15, 2025